诺诚健华(90009)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

90009 诺诚健华

休市中 12-27 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本2.25亿
成交额0.00	换手率0.00%	流通股本2,503万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"90009","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":0,"timestamp":1735286400000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":25034000,"shares":225290000,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"12-27 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735522200000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1735263000000,1735272000000],[1735275600000,1735286400000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":12.56,"timestamp":1735282800000,"preClose":12.16,"halted":0,"volume":4885000,"delay":0,"premium":"-100.00"}},"requestUrl":"/m/hq/s/90009/tweets","defaultTab":"tweets","newsList":[{"id":"2127200828","title":"诺诚健华成功举办首届投资者研发日活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2127200828","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2127200828?lang=zh_cn&edition=full","pubTime":"2021-04-15 13:54","pubTimestamp":1618466040,"startTime":"0","endTime":"0","summary":"北京2021年4月15日 /美通社/ -- 诺诚健华今日成功举办以“科学驱动创新”为主题的研发日线上线下活动。诺诚健华管理层团队分享了公司最新的研发、临床前以及临床试验进展，并和线上线下众多投资者和分析师进行了深入沟通和交流。研发日上，诺诚健华联合创始人、董事长兼首席执行官崔霁松博士携公司临床开发、商务拓展、研发和商业化高管集体出席。诺诚健华经过五年的快速发展，各方面取得重大进展。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/3343745_ZH43745_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["09969","90009"],"gpt_icon":0},{"id":"2127072585","title":"诺诚健华：公司新药奥布替尼获批在国内开展临床II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2127072585","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2127072585?lang=zh_cn&edition=full","pubTime":"2021-04-15 09:25","pubTimestamp":1618449900,"startTime":"0","endTime":"0","summary":"【诺诚健华：公司新药奥布替尼获批在国内开展临床II期研究】4月14日，诺诚健华宣布，公司旗下布鲁顿酪氨酸激酶（BTK）抑制剂奥布替尼用于治疗多发性硬化（MS）已经通过中国国家药品监督管理局（NMPA）...","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202104151885438464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["90009","09969"],"gpt_icon":0},{"id":"2127252770","title":"港股异动 | 诺诚健华-B(09969)涨超7% 奥布替尼获国家药监局批准开展治疗多发","url":"https://stock-news.laohu8.com/highlight/detail?id=2127252770","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2127252770?lang=zh_cn&edition=full","pubTime":"2021-04-14 15:41","pubTimestamp":1618386116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华-B宣布，公司旗下布鲁顿酪氨酸激酶抑制剂奥布替尼用于治疗多发性硬化已经通过中国国家药品监督管理局的临床研究用新药审评，获批在中国开展临床II期研究。截至发稿，诺诚健华涨7.03%，报20.55港元，成交额1.99亿港元。2020年11月，奥布替尼获美国FDA批准开展治疗多发性硬化临床II期研究。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2021/04/14154132371805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["90009","09969"],"gpt_icon":0},{"id":"2127047291","title":"诺诚健华－Ｂ(09969-HK)涨8.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2127047291","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2127047291?lang=zh_cn&edition=full","pubTime":"2021-04-14 13:42","pubTimestamp":1618378920,"startTime":"0","endTime":"0","summary":"诺诚健华-B(09969-HK)截至13:41上涨8.85%，现报20.9港元，涨1.7港元。成交518万股，涉资1.054亿元。","market":"us","thumbnail":"https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202104141884108958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["90009","09969"],"gpt_icon":0},{"id":"2127047898","title":"诺诚健华奥布替尼获国家药监局批准开展治疗多发性硬化临床II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2127047898","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2127047898?lang=zh_cn&edition=full","pubTime":"2021-04-14 09:37","pubTimestamp":1618364220,"startTime":"0","endTime":"0","summary":"2020年11月，奥布替尼获美国FDA批准开展治疗多发性硬化临床II期研究。奥布替尼是诺诚健华自主研发的具高度靶标选择性的新型BTK抑制剂，可用于治疗自身免疫性疾病，目前正在中国及美国进行多中心、多适应症的临床试验，显示了良好的靶点占有率和安全性。现有多个新药产品处于商业化、临床及临床前研发阶段。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-04-14/doc-ikmyaawa9565055.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-04-14/doc-ikmyaawa9565055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009","09969"],"gpt_icon":0},{"id":"2127551015","title":"诺诚健华牵手暨南大学 开展创新药功效评价等合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2127551015","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2127551015?lang=zh_cn&edition=full","pubTime":"2021-04-13 17:41","pubTimestamp":1618306891,"startTime":"0","endTime":"0","summary":"新京报讯(记者张秀兰)4月13日，港股上市公司诺诚健华宣布，与暨南大学达成共识，在科学研究、人才交流、产业合作等领域展开战略合作，涉及聚焦创新药功效评价等。诺诚健华和暨南大学将开展 ...","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20210413/c628531188.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20210413/c628531188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["06978","159992","90014","90009"],"gpt_icon":0},{"id":"2127947870","title":"诺诚健华和暨南大学达成校企战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2127947870","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2127947870?lang=zh_cn&edition=full","pubTime":"2021-04-13 11:39","pubTimestamp":1618285140,"startTime":"0","endTime":"0","summary":"中国广州2021年4月13日 /美通社/ -- 为深入贯彻落实国家《“健康中国2030”规划纲要》，加快生物医药行业技术创新，更好服务广东省医疗健康产业发展，广州诺诚健华医药科技有限公司今天和暨南大学达成共识，在科学研究、人才交流、产业合作等领域展开战略合作。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/3340355_ZH40355_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["09969","90009"],"gpt_icon":0},{"id":"2123224119","title":"诺诚健华-B(09969)委任谢榕刚为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2123224119","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123224119?lang=zh_cn&edition=full","pubTime":"2021-03-31 19:52","pubTimestamp":1617191578,"startTime":"0","endTime":"0","summary":"诺诚健华-B(09969)公布，林利军辞任非执行董事，自2021年3月31日起生效...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_16.jpeg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_16.jpeg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/440608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["90009","09969"],"gpt_icon":0},{"id":"2123260880","title":"高盛：予诺诚健华-B(09969)“买入”评级 目标价升至21港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2123260880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123260880?lang=zh_cn&edition=full","pubTime":"2021-03-30 14:52","pubTimestamp":1617087130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研究报告，予诺诚健华-B“买入”评级，目标价升至21港元。该行表示，公司在研的BTK抑制剂奥布替尼今年首季商业化进度理想，正计划将销售团队扩充至200人，今年内覆盖内地900家医院。另外，该行认为今年下半年潜在的国家医保药品目录谈判或为诺诚健华今年的增长动力之一，参考市场上其他BTK抑制剂Brukinsa及Imbruvica定价，认为对BTK抑制剂市场价格有支持作用。","market":"hk","thumbnail":"https://static.tigerbbs.com/8e87285f5f61644eaba65898e6ccf2bf","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8e87285f5f61644eaba65898e6ccf2bf"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/438372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","90009"],"gpt_icon":0},{"id":"2123267208","title":"高盛上调诺诚健华-B(09969.HK)目标价至21元  评级「买入」","url":"https://stock-news.laohu8.com/highlight/detail?id=2123267208","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123267208?lang=zh_cn&edition=full","pubTime":"2021-03-30 14:01","pubTimestamp":1617084088,"startTime":"0","endTime":"0","summary":"高盛发表研究报告指，诺诚健华-B  去年下半年录亏损5,700万元人民币，主要来自研发费用按年增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。高盛对诺诚健华予以「买入」评级，以反映2月份配股所得资金，以及公司将於今明两年加大研发投入，但预期今年及明年净亏损5.85亿及3.01亿元人民币，目标价上调至21元。","market":"us","thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1087753&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["09969","90009"],"gpt_icon":0},{"id":"2122402186","title":"诺诚健华2020年财报：收入超2.7亿元，研发投入同增近90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2122402186","media":"秘丛丛","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2122402186?lang=zh_cn&edition=full","pubTime":"2021-03-27 14:12","pubTimestamp":1616825536,"startTime":"0","endTime":"0","summary":"3月26日，诺诚健华发布截至2020年12月31日的2020年全年业绩报告和公司进展。该公司收入和其他收益由2019年的1.057亿元增加至2020年的2.727亿元，研发支出由2019年2.131亿元增加到2020年的4.028亿元。在亏损方面，诺诚健华由2019年的21.504亿元减少至2020年的4.643亿元。其中诺诚健华研发的BTK抑制剂奥布替尼于2020年12月在国内获批上市，这也是诺诚健华首款上市药物。今年2月3日，高瓴资本成为诺诚健华战略投资者，同时维梧资本继续增持。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.iyiou.com/news/202103271015961","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"iyiou_stock","symbols":["90009"],"gpt_icon":0},{"id":"2122740361","title":"6至8个药物将进入临床，诺诚健华研发支出接近翻番","url":"https://stock-news.laohu8.com/highlight/detail?id=2122740361","media":"腾讯自选股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2122740361?lang=zh_cn&edition=full","pubTime":"2021-03-26 20:42","pubTimestamp":1616762520,"startTime":"0","endTime":"0","summary":"6至8个药物将进入临床，诺诚健华研发支出接近翻番 来源：北京日报客户端在接下来的18个月，诺诚健华将有6至8个候选药物进入临床，从而使其进入临床阶段的药物将增加到10多个。3月26日，北京生物医药高科技公司诺诚健华发布的2020年全年业绩报告和公司进展还显示，其研发支出已由2019年的2.131亿元增加到2020年的4.028亿元。其现有多个新药产品已处于商业化、临床及临床前研发阶段。","market":"sh","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-26/doc-ikknscsk1885255.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-26/doc-ikknscsk1885255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009"],"gpt_icon":0},{"id":"2122479086","title":"诺诚健华发布2020年全年业绩报告和公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2122479086","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2122479086?lang=zh_cn&edition=full","pubTime":"2021-03-26 19:35","pubTimestamp":1616758500,"startTime":"0","endTime":"0","summary":"北京2021年3月26日 /美通社/ -- 诺诚健华今日发布截至2020年12月31日的2020年全年业绩报告和公司进展。初步临床结果令人鼓舞，计划2021年下半年公布数据。随着奥布替尼获批上市，2021年公司收入来源将更加多元化。 想要了解诺诚健华2020年全年业绩绩报告财务数据，敬请登录进行查询。电话会议信息 诺诚健华将在北京时间3月29日上午9:00举行电话会议。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/3323076_ZH23076_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["09969","90009"],"gpt_icon":0},{"id":"2122479820","title":"诺诚健华-B(09969.HK)年度亏损减少至4.64亿元 研发成本达4.03亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2122479820","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2122479820?lang=zh_cn&edition=full","pubTime":"2021-03-26 19:21","pubTimestamp":1616757668,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨诺诚健华-B发布公告，截至2020年12月31日止年度，公司收益由上年度的人民币120万元增加至人民币140万元，主要由于南京诺诚健华向第三方提供的服务订单增加所致。年内亏损由上年度的人民币21.5亿元减少至该年度的人民币4.64亿元。研发成本由上年度的人民币2.13亿元增加至该年度的人民币4.03亿元，该增加主要是由于公司扩展临床试验及股份支付增加所致。","market":"hk","thumbnail":"https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/news/detail.html?id=503202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["90009","09969"],"gpt_icon":0},{"id":"2122479806","title":"诺诚健华-B(09969)2020年年内亏损约4.64亿元 同比减少约78.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2122479806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2122479806?lang=zh_cn&edition=full","pubTime":"2021-03-26 19:19","pubTimestamp":1616757543,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华-B 公布2020年业绩，收益约人民币136.4万元，同比增长9.4%;其他收入及收益增加159.9%至2.71亿元;研发成本约4.03亿元，同比增长89%;年内亏损约4.64亿元，同比减少约78.41%;每股亏损0.48元，不派息。研发成本增加主要归因于：研发僱员成本由人民币5020万元增加至8370万元;第三方合约成本由人民币3830万元增加至5530万元;直接临床试验开支由人民币3750万元增加至5070万元;及以股份支付薪酬由人民币5720万元增加至1.716亿元。","market":"hk","thumbnail":"https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/436102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","90009"],"gpt_icon":0},{"id":"2122092476","title":"诺诚健华-B(09969.HK)全年亏损收窄至4.64亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2122092476","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2122092476?lang=zh_cn&edition=full","pubTime":"2021-03-26 19:09","pubTimestamp":1616756987,"startTime":"0","endTime":"0","summary":"诺诚健华-B  公布截至去年12月底止全年业绩，营业额136.4万元人民币(下同)，按年升9.4%。亏损收窄至4.64亿元，上年同期蚀21.41亿元；每股亏损0.48元。不派息。(ek/k)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":"https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/4eb8717d5f99acf9a964a1268bca53d6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1086591&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["CYB","09969","90009","UCmain","CNHmain"],"gpt_icon":0},{"id":"2120112747","title":"诺诚健华-B盘中异动 下午盘股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2120112747","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2120112747?lang=zh_cn&edition=full","pubTime":"2021-03-19 13:32","pubTimestamp":1616131939,"startTime":"0","endTime":"0","summary":"2021年03月19日下午盘13时32分，诺诚健华-B股票出现异动，股价大幅下跌5.13%。截至发稿，该股报18.900港元/股，成交量344.8万股，换手率0.23%，振幅4.52%。诺诚健华-B股票所在的生物技术行业中，整体跌幅为6.98%。诺诚健华-B公司简介：诺诚健华医药有限公司是一家主要从事生物医药业务的投资控股公司。消息层面，截至13时32分，诺诚健华-B股票正面舆情新闻比例25%。","market":"hk","thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202103191332197dce4447&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202103191332197dce4447&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","90009"],"gpt_icon":0},{"id":"2120925169","title":"诺诚健华-B(09969-HK)涨3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2120925169","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2120925169?lang=zh_cn&edition=full","pubTime":"2021-03-18 15:43","pubTimestamp":1616053380,"startTime":"0","endTime":"0","summary":"原标题：【异动股】诺诚健华－Ｂ(09969-HK)涨3.65%诺诚健华-B(09969-HK)截至15:39上涨3.65%，现报19.9港元，涨0.7港元。成交506万股，涉资1.007亿元。（文章来源：财华社）","market":"hk","thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202103181748247c07bfb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202103181748247c07bfb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["90009","09969"],"gpt_icon":0},{"id":"2120648156","title":"【异动股】诺诚健华－Ｂ(09969-HK)涨3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2120648156","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2120648156?lang=zh_cn&edition=full","pubTime":"2021-03-18 15:39","pubTimestamp":1616053190,"startTime":"0","endTime":"0","summary":"【财华社讯】诺诚健华－Ｂ(09969-HK)截至15:39上涨3.65%，现报19.9港元，涨0.7港元。成交506万股，涉资1.007亿元。（出处：FinetAI）","market":"us","thumbnail":"https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2021/03/18153932157047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["90009","09969"],"gpt_icon":0},{"id":"2119892970","title":"施一公创立的诺诚健华拟科创板上市，港股大涨至近300亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2119892970","media":"DeepTech深科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2119892970?lang=zh_cn&edition=full","pubTime":"2021-03-15 16:28","pubTimestamp":1615796880,"startTime":"0","endTime":"0","summary":"施一公创立的诺诚健华拟科创板上市，港股大涨至近300亿港元 来源：DeepTech深科技2021年3月11日，诺诚健华董事会决议拟发行人民币股份及于上海证券交易所科创板上市。2021年3月12日，诺诚健华市值已接近300亿港元，达到了291亿港元。自成立以来，诺诚健华深受资本青睐，2020年3月，诺诚健华通过适用“港股18A”新政的方式登陆港交所，募资资金超20亿港元。","market":"us","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-15/doc-ikknscsi5282060.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-15/doc-ikknscsi5282060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0249},{"period":"3month","weight":-0.0263},{"period":"6month","weight":0.1339},{"period":"1year","weight":0.1788},{"period":"ytd","weight":0.1785}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药业务的投资控股公司。公司发现、研发及商业化潜在同类最佳及首创的用于治疗癌症及自身免疫性疾病的药物。公司建立了具有内部研发能力的一体化生物医药平台，包括药物靶目标识别和验证、临床前评估、临床试验设计和执行、药物制造和质量控制，以及商业化生产及销售。","exchange":"SEHK","name":"诺诚健华","nameEN":"InnoCare Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(90009)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(90009)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,90009,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(90009)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(90009)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}